Search

Your search keyword '"Mabuchi, Seiji"' showing total 680 results
Start Over Author "Mabuchi, Seiji"
680 results on '"Mabuchi, Seiji"'

6. Robotic salvage radical hysterectomy for locally recurrent cervical cancer: A comparison with open surgery in a single‐surgeon series.

Author

Mabuchi, Seiji, Maeda, Michihide, Sakata, Mina, Matsuzaki, Shinya, Matsumoto, Yuri, Kamiura, Shoji, and Kimura, Tadashi

Subjects
*BLOOD loss estimation, *SURGICAL robots, *CERVICAL cancer, *OVERALL survival, *SURVIVAL analysis (Biometry)
Abstract

Aim Methods Results Conclusion To compare the surgical and oncologic outcomes between patients with locally recurrent cervical cancer undergoing robotic‐assisted salvage radical hysterectomy (RH) and those undergoing conventional open salvage RH, performed by a single surgeon.This retrospective comparative observational study utilized data obtained from consecutive patients with locally recurrent cervical cancer, developed after definitive radiotherapy. These patients either underwent robot‐assisted RH (robotic group) or conventional open RH (open group). Clinicopathological characteristics, surgical outcomes, and oncological outcomes were compared between the two groups.The operative time was slightly longer in the robotic group; however, this difference was not statistically significant. Estimated blood loss was significantly lower in the robotic group (median; 0 mL [robotic group] vs. 700 mL [open group]: p < 0.01). The incidence of intraoperative and early and late complications did not statistically differ between the two groups. The mean follow‐up was 29.0 and 17.1 months in the open and robotic groups, respectively. Disease recurrence rates were similar between the two groups (40% [robotic group] vs. 44.4% [open group]). Kaplan–Meier survival analysis for progression‐free survival and overall survival did not show statistically significant differences between the two groups.Robot‐assisted salvage RH in women with locally recurrent cervical cancer showed perioperative and oncological outcomes comparable to those of the open procedure. Although our results suggest that the robot‐assisted approach is as good as or better than the open approach, further investigation is required to establish a more robust conclusion. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan.

Author

Kunimasa, Kei, Sugimoto, Naotoshi, Yamasaki, Tomoyuki, Kukita, Yoji, Fujisawa, Fumie, Inoue, Tazuko, Yamaguchi, Yuko, Kitasaka, Mitsuko, Sakai, Daisuke, Honma, Keiichiro, Wakamatsu, Toru, Yamamoto, Sachiko, Hayashi, Takuji, Mabuchi, Seiji, Okuno, Jun, Kawamura, Takahisa, Kai, Yugo, Urabe, Makiko, and Nishimura, Kazuo

Subjects
PROGRESSION-free survival, TURNAROUND time, CLINICAL trials, INDIVIDUALIZED medicine, TREATMENT effectiveness
Abstract

Introduction: Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness. Methods: We analyzed data from advanced solid tumor patients who underwent CGP panel between December 2019 and May 2023 at the Osaka International Cancer Institute. Patient demographics, specimen details, and expert panel assessments were collected. Turnaround time (TAT) and genomically matched therapy outcomes were analyzed. Gene alterations and their co‐occurrence patterns were also assessed. Results: Among 1437 patients, 1096 results were available for analysis. The median TAT was 63 [28–182] days. There were 667 (60.9%) cases wherein recommended clinical trials were presented and there were 12 (1.1%) cases that could be enrolled in the trial and 25 (2.3%) cases that could lead to therapies under insurance reimbursement. The median progression free survival of the trial treatment was 1.58 months (95% CI: 0.66–4.37) in clinical trials and 3.66 months (95% CI: 2.14–7.13) in treatment under insurance. Pathologic germline variants were confirmed in 15 patients (1.3%). Co‐alteration of CDKN2A, CDKN2B, and MTAP was significantly observed in overall population. Conclusion: The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Laparoscopic Radical Hysterectomy

Author

Kobayashi, Eiji, Takiuchi, Tsuyoshi, Matsuzaki, Shinya, Matsumoto, Yuri, Kodama, Michiko, Hashimoto, Kae, Mabuchi, Seiji, Ueda, Yutaka, Sawada, Kenjiro, Tomimatu, Takuji, Yoshino, Kiyoshi, Kimura, Tadashi, Konishi, Ikuo, Series Editor, Katabuchi, Hidetaka, Series Editor, and Mikami, Mikio, editor

Published
2019
Full Text
View/download PDF

16. Extraovarian seromucinous borderline tumor: Case report and literature review.

Author

Sakata, Mina, Mabuchi, Seiji, Maeda, Michihide, Nagata, Shigenori, Tanaka, Junichiro, and Kamiura, Shoji

Subjects
*TUMOR diagnosis, *HYSTERECTOMY, *PAPILLARY carcinoma, *RARE diseases, *POSTMENOPAUSE, *TUMOR markers, *TREATMENT effectiveness, *ENDOMETRIOSIS, *TUMOR antigens, TUMOR surgery, CERVIX uteri tumors
Abstract

Seromucinous borderline tumors (SMBT) are papillary neoplasms without invasive capabilities. Originally categorized as ovarian tumors, SMBT, being an endometriosis‐related tumor, can manifest beyond the ovaries. To date, only four cases of extraovarian SMBT have been documented in literature. In this report, we present our experience with the first case of SMBT in the uterine cervix, which exhibited highly elevated CA19‐9 levels. The patient, initially clinically diagnosed with cervical cancer, underwent treatment with radical hysterectomy and was later pathologically diagnosed with SMBT of the uterine cervix. While extraovarian SMBT, especially in the uterine cervix, is extremely rare, this condition should be considered in patients with cervical masses lacking pathological evidence of malignant disease but displaying elevated CA19‐9 levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy

Author

Takekuma, Munetaka, Takahashi, Fumiaki, Mabuchi, Seiji, Kudaka, Wataru, Horie, Koji, Ikeda, Mariko, Shikama, Ayumi, Mitsuhashi, Akira, Nagao, Shoji, Suzuki, Shiro, Mizuno, Mika, Nishio, Shin, Tokunaga, Hideki, Ota, Yukinobu, Kasamatsu, Takahiro, Kitagawa, Ryo, Toita, Takafumi, Kobayashi, Hiroaki, Ishikawa, Mitsuya, and Yaegashi, Nobuo

Published
2020
Full Text
View/download PDF

37. Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary

Author

Miyake, Ryuta, Yamanaka, Shoichiro, Matsubara, Sho, Mabuchi, Seiji, Miyake, Ryuta, Yamanaka, Shoichiro, Matsubara, Sho, and Mabuchi, Seiji

Abstract

Background/Aim: To evaluate the antitumor effects of Plitidepsin against clear cell carcinoma (CCC) of the ovary. Materials and Methods: The expression of eEF1A2 in ovarian cancer was assessed by immunohistochemistry. Using ovarian CCC cell lines, the antitumor effect of Plitidepsin was assessed both in vitro and in vivo. By over-expressing or knocking down the eEF1A2 expression, we investigated the role of eEF1A2 in the sensitivity of CCC cells to Plitidepsin. Results: Immunoreactivity to eEF1A2 was observed in 76.2% of CCC, which was significantly higher than other histological subtypes of ovarian cancer. Plitidepsin exhibited significant antitumor activity toward chemonaive and chemoresistant CCC cells both in vitro and in vivo. Ectopic expression of eEF1A2 in CCC cells resulted in increased sensitivity to Plitidepsin. In contrast, eEF1A2 knockdown decreased sensitivity of CCC cells to plitidepsin. Conclusion: Plitidepsin, a novel anti-cancer agent that targets eEF1A2, may be a promising agent for treating ovarian CCC.Clear cell carcinoma (CCC) of the ovary is known to be less sensitive to platinum-based frontline chemotherapy, and advanced-stage CCC is known to be associated with a worse prognosis than the more common histological subtype of serous adenocarcinoma (SAC). The lack of an effective chemotherapy for recurrent CCC is another important clinical problem (1). Therefore, novel strategies for both first-line treatment for advanced-stage CCC and salvage treatment for recurrent disease are needed. Plitidepsin (Aplidin®) is a novel anti-cancer agent currently investigated in late phases of clinical development. In 2018, the Australian regulatory agency approved Plitidepsin in combination with dexamethasone for the treatment of multiple myeloma. Plitidepsin was originally isolated from the Mediterranean tunicate Aplidium albicans in 1988: currently it is chemically synthesized by Pharma Mar (Madrid, Spain) (2). According to previous preclinical studies, Plitid

Published
2023

39. Relationship between Abnormal Placenta and Obstetric Outcomes: A Meta-Analysis

Author

Matsuzaki, Shinya, primary, Ueda, Yutaka, additional, Matsuzaki, Satoko, additional, Sakaguchi, Hitomi, additional, Kakuda, Mamoru, additional, Lee, Misooja, additional, Takemoto, Yuki, additional, Hayashida, Harue, additional, Maeda, Michihide, additional, Kakubari, Reisa, additional, Hisa, Tsuyoshi, additional, Mabuchi, Seiji, additional, and Kamiura, Shoji, additional

Published
2023
Full Text
View/download PDF

41. Supplemental Table 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

42. Supplemental Figure Legend from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figure 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

44. Supplemental Table 2 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 1 - 6, Table 1 from Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells

Author

Nakamura, Koji, primary, Sawada, Kenjiro, primary, Kinose, Yasuto, primary, Yoshimura, Akihiko, primary, Toda, Aska, primary, Nakatsuka, Erika, primary, Hashimoto, Kae, primary, Mabuchi, Seiji, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, Lengyel, Ernst, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results